Logo for Diamyd Medical

Diamyd Medical Investor Relations Material

Latest events

Logo for Diamyd Medical

Q3 2024

Diamyd Medical
Logo for Diamyd Medical

Q3 2024

26 Jun, 2024
Logo for Diamyd Medical

Q2 2024

27 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Diamyd Medical

Access all reports
Diamyd Medical AB is a biotechnology company headquartered in Stockholm, Sweden, specializing in the development of immune modifying therapies for diabetes. The company is actively engaged in the pharmaceutical development field, focusing on two innovative disease-modifying drugs: Diamyd, an antigen-specific immunotherapy, and Remygen, an oral regenerative and immunomodulatory therapeutic. These drugs are undergoing clinical trials and are designed to address the underlying causes of diabetes, including dysfunction and loss of the pancreas's insulin-producing cells. Diamyd Medical operates a manufacturing facility in Umeå and leverages a global network of clinics, researchers, and production units for its development efforts. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq First North.